Purchase this article with an account.
Domenico Massaro, Francesco Pichi, Paola Carrai, Andrea Lembo, Mariachiara Morara, Antonio Ciardella, Paolo Nucci; COMBINATION THERAPY WITH DEXAMETHASONE INTRAVITREAL IMPLANT AND MACULAR GRID LASER IN PATIENTS WITH BRANCH RETINAL VEIN OCCLUSION. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):3752.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To test a combination of dexamethasone intravitreal implant with macular grid laser for macular edema in patients with branch retinal vein occlusion.
In this prospective interventional, randomized, multi-center study patients with macular edema secondary to BRVO underwent an Ozurdex® intravitreal implant at baseline. After one month, patients were randomly assigned to 2 study groups. Patients in Group 1 were followed up monthly and retreated with Ozurdex® implant whenever there was a recurrence of macular edema or a decrease in BCVA. In Group 2 patients macular grid laser was performed between week 6 and 8. After that, patients were followed up and retreated as for Group 1.
In Group 1 at the 4 months visit, mean BCVA was 0.49 ± 0.35 logMAR and CRT was to 391 ± 172 µm; both improved significantly at 6 months, to 0.32 ± 0.29 and 322 ± 160 µm respectively. In Group 2, foveal thickness was reduced significantly to 291 ± 76 µm at 4 months, and BCVA improved to 0.25 ± 0.20. At the final visit, BCVA was 0.18 ± 0.14 logMAR and mean CRT was 271 ± 44 µm. The number of Ozurdex® implants at 4 months was 12/25 (48%) in Group 1 vs 3/25 (12%) in Group 2 (p=0.012). At 6 months 3/25 (12%) in Group 1 vs 0/25 (0%) in Group 2 (p=0.23) were retreated.
The combination of Ozurdex® implant and macular grid is synergistic in increasing visual acuity and lengthening the time between injections.
This PDF is available to Subscribers Only